923 results on '"Widemann, Brigitte C."'
Search Results
2. Virtual multi-institutional tumor board: a strategy for personalized diagnoses and management of rare CNS tumors
3. Imaging as an early biomarker to predict sensitivity to everolimus for progressive NF2-related vestibular schwannoma
4. Germline findings in cancer predisposing genes from a small cohort of chordoma patients
5. MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus.
6. Retrospective Cohort Analysis of the Impact of Puberty on Plexiform Neurofibroma Growth in Patients with Neurofibromatosis Type 1
7. Advancing RAS/RASopathy therapies: An NCI‐sponsored intramural and extramural collaboration for the study of RASopathies
8. Doxorubicin pharmacokinetics and toxicity in patients with aggressive lymphoma and hepatic impairment
9. Low mutation burden and frequent loss of CDKN2A/B and SMARCA2, but not PRC2, define pre-malignant neurofibromatosis type 1-associated atypical neurofibromas
10. First International Conference on RASopathies and Neurofibromatoses in Asia: Identification and advances of new therapeutics
11. Proceedings of the fifth international RASopathies symposium: When development and cancer intersect
12. Single-cell sequencing reveals activation of core transcription factors in PRC2-deficient malignant peripheral nerve sheath tumor
13. Platform trial design for neurofibromatosis type 1, NF2-related schwannomatosis and non-NF2-related schwannomatosis: A potential model for rare diseases.
14. Advances, challenges and progress in pediatric hematology and oncology
15. The characteristics of 76 atypical neurofibromas as precursors to neurofibromatosis 1 associated malignant peripheral nerve sheath tumors.
16. 2016 Children's Tumor Foundation conference on neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis
17. Genetically engineered minipigs model the major clinical features of human neurofibromatosis type 1
18. Diagnosis and Management of Benign Nerve Sheath Tumors in NF1: Evolution from Plexiform to Atypical Neurofibroma and Novel Treatment Approaches
19. Acceptance and commitment therapy for adolescents and adults with neurofibromatosis type 1, plexiform neurofibromas, and chronic pain: Results of a randomized controlled trial
20. Neurofibromatosis Type 1–Associated MPNST State of the Science: Outlining a Research Agenda for the Future
21. SARC006: Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated Chemotherapy-Naive Malignant Peripheral Nerve Sheath Tumors.
22. Platform trial design for neurofibromatosis type 1, NF2-related schwannomatosis and non-NF2-related schwannomatosis:A potential model for rare diseases
23. Early detection of malignant and pre-malignant peripheral nerve tumors using cell-free DNA fragmentomics
24. Development and psychometric testing of a pediatric chronic graft-versus-host disease symptom scale: protocol for a two-phase, mixed methods study
25. Cabozantinib for neurofibromatosis type 1–related plexiform neurofibromas: a phase 2 trial
26. Current status and recommendations for biomarkers and biobanking in neurofibromatosis
27. Sleep and pulmonary outcomes for clinical trials of airway plexiform neurofibromas in NF1
28. The Fourth International Symposium on Genetic Disorders of the Ras/MAPK pathway
29. Supplementary Fig 12 from Longitudinal Natural History Study of Children and Adults with Rare Solid Tumors: Initial Results for First 200 Participants
30. Supplementary Fig 4 from Longitudinal Natural History Study of Children and Adults with Rare Solid Tumors: Initial Results for First 200 Participants
31. Data from Longitudinal Natural History Study of Children and Adults with Rare Solid Tumors: Initial Results for First 200 Participants
32. TABLE 1 from Longitudinal Natural History Study of Children and Adults with Rare Solid Tumors: Initial Results for First 200 Participants
33. Supplementary Fig 5 from Longitudinal Natural History Study of Children and Adults with Rare Solid Tumors: Initial Results for First 200 Participants
34. FIGURE 1 from Longitudinal Natural History Study of Children and Adults with Rare Solid Tumors: Initial Results for First 200 Participants
35. Supplementary Tables S1 and S2 from Longitudinal Natural History Study of Children and Adults with Rare Solid Tumors: Initial Results for First 200 Participants
36. FIGURE 4 from Longitudinal Natural History Study of Children and Adults with Rare Solid Tumors: Initial Results for First 200 Participants
37. Supplementary Fig 9 from Longitudinal Natural History Study of Children and Adults with Rare Solid Tumors: Initial Results for First 200 Participants
38. FIGURE 2 from Longitudinal Natural History Study of Children and Adults with Rare Solid Tumors: Initial Results for First 200 Participants
39. Supplementary Fig 6 from Longitudinal Natural History Study of Children and Adults with Rare Solid Tumors: Initial Results for First 200 Participants
40. Supplementary Fig 8 from Longitudinal Natural History Study of Children and Adults with Rare Solid Tumors: Initial Results for First 200 Participants
41. Supplementary Fig 2 from Longitudinal Natural History Study of Children and Adults with Rare Solid Tumors: Initial Results for First 200 Participants
42. Supplementary Fig 3 from Longitudinal Natural History Study of Children and Adults with Rare Solid Tumors: Initial Results for First 200 Participants
43. Supplementary Fig 7 from Longitudinal Natural History Study of Children and Adults with Rare Solid Tumors: Initial Results for First 200 Participants
44. TABLE 2 from Longitudinal Natural History Study of Children and Adults with Rare Solid Tumors: Initial Results for First 200 Participants
45. FIGURE 3 from Longitudinal Natural History Study of Children and Adults with Rare Solid Tumors: Initial Results for First 200 Participants
46. Longitudinal Natural History Study of Children and Adults with Rare Solid Tumors: Initial Results for First 200 Participants
47. A molecular basis for neurofibroma-associated skeletal manifestations in NF1
48. Current status of MEK inhibitors in the treatment of plexiform neurofibromas
49. Phase II/III trial of a pre‐transplant farnesyl transferase inhibitor in juvenile myelomonocytic leukemia: A report from the Children's Oncology Group
50. CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.